Format

Send to

Choose Destination
Invest New Drugs. 2011 Oct;29(5):1090-3. doi: 10.1007/s10637-010-9458-7. Epub 2010 Jun 5.

Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.

Author information

1
Center for Research on Angiogenesis Inhibitor, Université Paris Descartes, AP-HP, Teaching Hospital Cochin, Paris, France. romain.coriat@cch.aphp.fr

Abstract

Recently, pneumatosis intestinalis has been described in patients receiving bevacizumab, a monoclonal antibody to VEGF-A. Pneumatosis intestinalis is a condition characterized by subserosal and submucosal gas-filled cysts in the gastrointestinal tract. We report on pneumatosis intestinalis in patients receiving oral anti-VEGF agents. Patients shared the following characteristics: long-term (> 4 months) exposure to anti-VEGF agents, lack of other factors predisposing to pneumatosis intestinalis, and lack of recent surgical intervention. Taken together, these observations suggest that pneumatosis intestinalis is a probable class-effect of anti-VEGF agents.

PMID:
20524036
DOI:
10.1007/s10637-010-9458-7
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center